ArticleJournal of eating disorders2025
Ketamine for treatment resistant depression in individuals with eating disorders: a comparison study.
Article in Journal of eating disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals with eating disorders (EDs) have an increased risk of treatment resistant depression (TRD) and treatment resistant bipolar disorder (TRBD) and a higher rate of suicidal ideation and death by suicide than individuals without EDs. Individuals with EDs are less responsive to conventional treatments for mood disorders than individuals without EDs. Ketamine has evidence for treatment of TRD and TRBD and for the treatment of acute suicidality. Ketamine has also been shown to be safe in individuals with EDs who are malnourished. This study is among the first to examine the efficacy of ketamine in TRD and TRBD in patients with co-occurring EDs at higher levels of care.
methodsParticipants were 85 adults admitted to an ED treatment facility who received subanesthetic intranasal generic ketamine compared to a sample of 85 adults matched for age, sex, gender, race, diagnosis, and level of care at admission admitted to the same facilities who did not receive ketamine. Participants completed the Eating Disorder Examination Questionnaire (EDE-Q), Patient Health Questionnaire-9 (PHQ-9), suicidal ideation (PHQ-9 Item 9) and Generalized Anxiety Disorder-7 (GAD-7) at admission and discharge.
resultsPatients receiving ketamine and matched controls were not significantly different on age, sex, gender, race, diagnosis, or level of care at admission. There were no significant differences between groups on admission for all EDE-Q subscales, PHQ-9, suicidal ideation, or GAD. All patients, irrespective of use of ketamine, improved significantly from admission to discharge on all outcomes. There were no significant differences between groups for change in all EDE-Q subscales, change in PHQ-9, change in suicidal ideation, or change in GAD-7. Patients receiving ketamine had significantly longer lengths of stay than controls (b = 0.39, p = .01). The lack of significant differences was maintained irrespective of predicting raw change, controlling for admission scores, or additionally controlling for length of stay.
conclusionsIn a population of individuals seeking higher level of care for an ED and controls matched for age, gender, sex, diagnosis, level of care, and race, treatment with ketamine was associated with significant reductions in depression and ED severity, but not more so than individuals not treated with ketamine. Findings from the study suggest that ketamine may be a viable treatment option for individuals with EDs, however, further research is needed to determine ketamine's efficacy in treating EDs with comorbid depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.